Aragen Life Sciences стала крупнейшим CRDMO-провайдером в Индии по числу решений

Incorporated in 2000, Aragen Life Sciences is a fully integrated contract research, development and manufacturing organisation serving global innovator companies and emerging firms in the life sciences industry. The company offers solutions across the drug development lifecycle, spanning contract discovery and pre-clinical research solutions, or CRO, and contract development and manufacturing solutions, or CDMO, for small molecules as well as biologics. With more than 25 years of operations, the company said it has become the largest CRDMO among assessed Indian peers in terms of the number of solutions offered across the drug development value chain as of March 31, 2026. It also said it is among the top three largest Indian CRDMOs in terms of operating revenue among assessed Indian peers, in a global CRDMO market estimated at $171 billion in fiscal 2026. Aragen Life Sciences said it focuses on life sciences companies engaged in new chemical entities and new biological entities, and served as a strategic partner to 591 customers globally in fiscal 2026. Its customers are spread across the United States, Europe, Japan, India and other APAC markets. Its customer base includes Big Pharma companies, large pharmaceutical companies, small biotechnology companies and mid-sized pharmaceutical companies across pharmaceuticals, biotechnology, animal health, agrochemicals and specialty chemicals. The company said it worked with 16 of the top 20 Big Pharma customers as of March 31, 2026. The company also said it has maintained a structured focus on environmental, social and governance initiatives and corporate governance practices, including sustainability commitments, responsible business conduct and board-led oversight supported by a professional management team. It received the Gold EcoVadis Sustainability Rating in fiscal 2026, placing it among the top 5 per cent of companies globally. It became a signatory to the Science Based Target Initiative in fiscal 2023 and an associate member of the Pharmaceutical Supply Chain Initiative in 2022. According to the draft papers, revenue from operations, profit for the year, adjusted EBITDA and adjusted profit for the year grew at a CAGR of 14.64 per cent, 26.86 per cent, 15.63 per cent and 29.91 per cent, respectively, to Rs 2,178.39 crore, Rs 257.64 crore, Rs 593.77 crore and Rs 283.99 crore, respectively, in FY26. It said it maintained a focus on capital efficiency, with ROCE at 18.18 per cent and ROE at 11.96 per cent. Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial are the book running lead managers to the issue.